🇺🇸 ZTlido in United States

FDA authorised ZTlido on 28 February 2018

Marketing authorisations

FDA — authorised 28 February 2018

  • Application: NDA207962
  • Marketing authorisation holder: SCILEX PHARMS
  • Local brand name: ZTLIDO
  • Indication: PATCH — TOPICAL
  • Status: approved

Read official source →

FDA

  • Status: approved

ZTlido in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is ZTlido approved in United States?

Yes. FDA authorised it on 28 February 2018; FDA has authorised it.

Who is the marketing authorisation holder for ZTlido in United States?

SCILEX PHARMS holds the US marketing authorisation.